Oncology Business Management | Specialty

Follicular Lymphoma: Defining Copanlisib

October 21st 2017

Follicular Lymphoma: Overview of Treatment Options

October 21st 2017

Follicular Lymphoma: Outcomes with Immunotherapy

October 21st 2017

NICE Rejects Treatments for Bladder and Thyroid Cancer

October 21st 2017

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

October 19th 2017

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

Dr. Zandberg on Biomarker Development in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Payer Payment Delays Are Escalating

October 13th 2017

As increasingly pricey therapies come on the market, payers have grown more cautious about issuing payment approvals.

Federal Indecisiveness Belies Significant Changes in Medicaid Policy State by State

October 13th 2017

Today’s healthcare landscape is rapidly evolving, with many trends emerging and policy changes under consideration that have far-reaching implications for cancer care.

Savings Improve Faster Than Care Quality in New Medical Home Pilot

October 12th 2017

Five years ago, Capital BlueCross asked community oncology practices in its network what kind of reimbursement model they would like to try as they worked to stay financially viable and independent.

Dr. Ross on Biomarker Research Development in Liver Metastasis

October 11th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastasis.

Dr. Geynisman on Sequencing of Agents for Kidney Cancer

October 3rd 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses challenges facing the sequencing of agents for patients with metastatic kidney cancer.

Experts Discuss Advanced Therapies in Relapsed/Refractory Multiple Myeloma

October 3rd 2017

The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.

HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017

Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017

Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017